by Nature
Scientists employed in vivo screening to identify genes that affect chimeric antigen receptor (CAR) T-cell persistence and function — findings that could inform efforts to improve treatment...
by Blood
Researchers suspect that glutamine dependency, a key metabolic feature of multiple myeloma (MM), contributes to the limited efficacy of chimeric antigen receptor (CAR) T-cell therapy in oncology...
by Blood Advances
A European study highlighted the positive effect of chimeric antigen receptor (CAR) T-cell therapy on patients' health-related quality of life (HRQoL) and ongoing challenges after treatment....
by Nature
Early Phase I study results demonstrate the promise of chimeric antigen receptor (CAR) T-cell therapy targeting both CD19 and BCMA cells in patients with systemic lupus erythematosus and...
by Blood
Acknowledging the limitations of murine and primary cell models in predicting clinical outcomes with chimeric antigen receptor (CAR) T cell therapy, researchers created an immunocompetent nonhuman...
by Blood
Innate lymphoid cells (ILCs) derived from hematopoietic stem cells mitigate graft-versus-host disease (GVHD) in human and mice models but, until now, how they do so has not been fully understood.